JPS62161725A - 悪性腫瘍防止剤 - Google Patents
悪性腫瘍防止剤Info
- Publication number
- JPS62161725A JPS62161725A JP17824186A JP17824186A JPS62161725A JP S62161725 A JPS62161725 A JP S62161725A JP 17824186 A JP17824186 A JP 17824186A JP 17824186 A JP17824186 A JP 17824186A JP S62161725 A JPS62161725 A JP S62161725A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- growth
- porphyrin
- patients
- malignant tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000011510 cancer Diseases 0.000 title claims abstract description 30
- 230000003449 preventive effect Effects 0.000 title claims 2
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 abstract description 23
- 229950003776 protoporphyrin Drugs 0.000 abstract description 23
- 230000012010 growth Effects 0.000 abstract description 11
- 206010027476 Metastases Diseases 0.000 abstract description 7
- 230000009401 metastasis Effects 0.000 abstract description 7
- 238000010606 normalization Methods 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000004614 tumor growth Effects 0.000 abstract description 4
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 abstract description 2
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 abstract description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 abstract description 2
- 229960003569 hematoporphyrin Drugs 0.000 abstract description 2
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 coproporphyrin Chemical compound 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000004033 porphyrin derivatives Chemical class 0.000 abstract 1
- 230000002354 daily effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000004324 lymphatic system Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical class N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17824186A JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17824186A JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51028506A Division JPS6052124B2 (ja) | 1975-03-17 | 1976-03-16 | 悪性腫瘍防止剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62161725A true JPS62161725A (ja) | 1987-07-17 |
| JPS638087B2 JPS638087B2 (https=) | 1988-02-19 |
Family
ID=16045061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17824186A Granted JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62161725A (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730666B1 (en) | 1998-11-08 | 2004-05-04 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
| JP2006527196A (ja) * | 2003-06-06 | 2006-11-30 | ユーカリオン，インコーポレイテッド | 経口で生体利用可能な低分子量メタロポルフィリン |
| JP2009155239A (ja) * | 2007-12-26 | 2009-07-16 | National Institute Of Advanced Industrial & Technology | Ｘ線治療用増感剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020241164A1 (ja) | 2019-05-24 | 2020-12-03 | 信越化学工業株式会社 | プラスチック用離型剤 |
-
1986
- 1986-07-29 JP JP17824186A patent/JPS62161725A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730666B1 (en) | 1998-11-08 | 2004-05-04 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
| JP2006527196A (ja) * | 2003-06-06 | 2006-11-30 | ユーカリオン，インコーポレイテッド | 経口で生体利用可能な低分子量メタロポルフィリン |
| JP2009155239A (ja) * | 2007-12-26 | 2009-07-16 | National Institute Of Advanced Industrial & Technology | Ｘ線治療用増感剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS638087B2 (https=) | 1988-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4393071A (en) | Method of treating gastric, mammary, lung and uterus tumors | |
| Karnofsky et al. | Triethylene melamine in the treatment of neoplastic disease: a compound with nitrogen-mustard-like activity suitable for oral and intravenous use | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| Arnott | The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma | |
| JPS62161725A (ja) | 悪性腫瘍防止剤 | |
| CN108125940B (zh) | 戊酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途 | |
| CURTIS et al. | Beta dimethylaminoethyl benzhydryl ether hydrochloride (benadryl) in treatment of urticaria | |
| US6602870B2 (en) | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same | |
| Hainsworth et al. | Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| Elzawawy | Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes | |
| Staley et al. | VARIOUS METHODS OF ADMINISTERING 5-FLUOROURACIL1, 2 | |
| JPS6052124B2 (ja) | 悪性腫瘍防止剤 | |
| RU2369396C2 (ru) | Фармацевтическая композиция, содержащая оксоплатин, его соли и производные | |
| TSUDA et al. | Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients | |
| Fielding et al. | Reversible arteriopathy following an ergotamine overdose in a heavy smoker | |
| Sawicky | THERAPY OF LUPUS ERYTHEMATOSUS: Bismuth Sodium Triglycollamate, Sodium Paraaminobenzoate and the Tocopherols (Vitamin E) | |
| US20020187956A1 (en) | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide | |
| JP6937065B1 (ja) | 間質性肺炎の治療剤 | |
| Prokopowycz | Agranulocytosis following use of chlorpromazine therapy | |
| RU2853399C1 (ru) | Способ повышения эффективности радиотерапии солидных новообразований в эксперименте | |
| Folman | Experience with mitomycin in the treatment of non-small cell lung cancer | |
| US3789124A (en) | Treatment of colitis ulcerosa | |
| Salmon et al. | Treatment of early breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: initial results of a brief and effective adjuvant program | |
| Cohen et al. | Experimental Radiotherapy of Abdominal Cancer II. Effect of a Flavonone (Rutin) on Radiation Reactions |